{"filing":{"accession_number":"0001829126-26-007881","cik":"0002079109","ticker":null,"company_name":"Veraxa Biotech Holding AG","form":"6-K","filing_date":"2026-07-27","report_date":"2026-07-27","primary_document":"veraxabiotechag_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079109/000182912626007881/veraxabiotechag_6k.htm"},"events":[{"id":20656,"run_id":18594,"accession_number":"0001829126-26-007881","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces the advancement of a novel bispecific antibody drug conjugate program (VXA-222) following successful achievement of a key technical milestone in VERAXA's alliance with OmniAb. The disclosure describes progression of a collaborative drug discovery program into its next phase, representing a material operational and strategic development for the emerging biotech company's pipeline. While not a discrete M\u0026A transaction, financing event, or executive change, this milestone advancement of a proprietary therapeutic candidate is a material operational event that would affect a reasonable investor's assessment of the company's progress and pipeline value.","company_name":"Veraxa Biotech Holding AG","ticker":null,"filing_date":"2026-07-27","form":"6-K","submitted_at":null,"items":[{"id":20080,"accession_number":"0001829126-26-007881","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the advancement of a novel bispecific antibody drug conjugate program (VXA-222) following successful achievement of a key technical milestone in VERAXA's alliance with OmniAb. The disclosure describes progression of a collaborative drug discovery program into its next phase, representing a material operational and strategic development for the emerging biotech company's pipeline. While not a discrete M\u0026A transaction, financing event, or executive change, this milestone advancement of a proprietary therapeutic candidate is a material operational event that would affect a reasonable investor's assessment of the company's progress and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:09:08.415839+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20080,"accession_number":"0001829126-26-007881","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the advancement of a novel bispecific antibody drug conjugate program (VXA-222) following successful achievement of a key technical milestone in VERAXA's alliance with OmniAb. The disclosure describes progression of a collaborative drug discovery program into its next phase, representing a material operational and strategic development for the emerging biotech company's pipeline. While not a discrete M\u0026A transaction, financing event, or executive change, this milestone advancement of a proprietary therapeutic candidate is a material operational event that would affect a reasonable investor's assessment of the company's progress and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:09:08.415839+00:00","company_name":"Veraxa Biotech Holding AG","ticker":null,"filing_date":"2026-07-27"}]}